Pioglitazone, nuclear receptors, and aerodigestive prevention

Research output: Contribution to journalReview article

Abstract

There has been intense interest in nuclear receptor targeting for cancer prevention. With the exception of estrogen antagonism in breast carcinoma there has not been widespread adoption or success of this strategy in clinical cancer prevention. Keith and colleagues have performed a careful study, which utilized the PPARg nuclear receptor agonist, pioglitazone, a common type II diabetes agent, in subjects at risk for lung carcinoma. Although the results are not promising with this strategy, the study provides evidence for feasibility accrual and biomarker strategies that could be utilized to gain additional insight in future trials.

Original languageEnglish (US)
Pages (from-to)641-643
Number of pages3
JournalCancer Prevention Research
Volume12
Issue number10
DOIs
StatePublished - 2019

Fingerprint Dive into the research topics of 'Pioglitazone, nuclear receptors, and aerodigestive prevention'. Together they form a unique fingerprint.

  • Cite this